{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"MPR Weekly Dose Podcast #274 \u2014 Ozempic Tablets; ALS Tx Fast Tracked; Phase 3 results for aficamten in HCM; Motion Sickness Drug Approved; Lantus Alternative","description":"Ozempic tablets are now available; investigational ALS treatment gains FDA Fast Track status; positive results for aficamten in non-obstructive hypertrophic cardiomyopathy; motion sickness drug Nereus now available; Lantus alternative Langlara gains approval. ","author_name":"MPR Weekly Dose","author_url":"https:\/\/www.empr.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/41218180\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/201736250"}